Gallbladder neuroendocrine tumor, grade 1/2

Summary

Gallbladder neuroendocrine tumor, grade 1/2 (MONDO:0015073) is a cancer. A subtype of digestive system neuroendocrine tumor, grade 1/2 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Phenotypes (HPO): 18

Clinical features

Signs & symptoms

Clinical features (HPO)

18 HPO clinical features (Orphanet curated; top 18 by frequency):

HPO ID	Term	Frequency
HP:0100574	Biliary tract neoplasm	Obligate (100%)
HP:0100634	Neuroendocrine neoplasm	Obligate (100%)
HP:0001046	Intermittent jaundice	Frequent (30-79%)
HP:0001082	Cholecystitis	Frequent (30-79%)
HP:0001541	Ascites	Frequent (30-79%)
HP:0001824	Weight loss	Frequent (30-79%)
HP:0002018	Nausea	Frequent (30-79%)
HP:0002039	Anorexia	Frequent (30-79%)
HP:0002574	Episodic abdominal pain	Frequent (30-79%)
HP:0002730	Chronic noninfectious lymphadenopathy	Frequent (30-79%)
HP:0003270	Abdominal distention	Frequent (30-79%)
HP:0005230	Biliary tract obstruction	Frequent (30-79%)
HP:0010638	Elevated alkaline phosphatase of hepatic origin	Frequent (30-79%)
HP:0012334	Extrahepatic cholestasis	Frequent (30-79%)
HP:0012432	Chronic fatigue	Frequent (30-79%)
HP:0030948	Elevated gamma-glutamyltransferase level	Frequent (30-79%)
HP:0004375	Neoplasm of the nervous system	Very rare (<1-4%)
HP:0012658	Abnormal brain FDG positron emission tomography	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	gallbladder neuroendocrine tumor, grade 1/2
Mondo ID	MONDO:0015073
Orphanet	100086
NCIT	C96918
UMLS	C3273116
MedGen	474749
GARD	0019761
Is cancer (heuristic)	yes

Also known as: gallbladder NET · gallbladder neuroendocrine tumor · gallbladder neuroendocrine tumour · gallbladder well differentiated endocrine tumor · gallbladder well differentiated endocrine tumor/carcinoma · gallbladder well differentiated endocrine tumour

Disease family

This is a subtype of digestive system neuroendocrine tumor, grade 1/2. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › gallbladder neuroendocrine tumor, grade 1/2

Related subtypes (9): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.